PharmaTech Integrates 2023 Track 2
THERAPIES
Focusing on new therapies and the technology developments required for them to realise their full potential
Welcome and Fireside Chat 1
Welcome and Opening Remarks
Dave Tudor | Managing Director | Medicines Manufacturing Innovation Centre, CPI
Fireside Chat 1: Future Industry Challenges
– What are the future challenges facing the Pharma industry?
– What role will Digital Innovation play?
Speakers include:
Ian McCubbin | Chair | RoslinCT | Chair | Cell and Gene Therapy Catapult
Ian Rees | Regulatory Affairs Consultant | DI REES Ltd
David Littlejohn | Special Advisor to the Principal | University of Strathclyde
Interviewed by:
Maureen Wedderburn | Non Executive Chair, Medicines Manufacturing Innovation Centre | CPI
Session 1: Oligo-new-cleotides
Addressing the unique analytical, manufacture and regulatory challenges for Oligonucleotides
FACILITATED BY
Barrie Cassey | Pharmaceutical and Biotechnology Technical Expert and Leader | CPI
PANELLISTS
Louis Diorazio | Senior Principal Scientist, New Modalities | AstraZeneca
Andrew Livingston | Chief Executive Officer and Co-Founder | Exactmer
Wendy Cross | CMC Matrix Leader | GSK
Sam Whitmarsh | Director of Analytical Science and Digital Transformation | CatSci Ltd
Session 3: Towards digital transformation of Chemistry, Manufacturing and Controls (CMC): Academic and Industry Perspectives
Joint presentation with both Ivan Marziano and Alastair Florence.
PANELLISTS
Ivan Marziano | Industry Board Chair for CMAC | Research Fellow for Pfizer
Alastair Florence | Director, Continuous Manufacturing and Advanced Crystallisation (CMAC) Research Hub | University of Strathclyde
Fireside Chat 2 and Closing Remarks
Fireside Chat 2: Transforming Drug Development
– Exploring Breakthrough Digital Technologies and System Thinking Approaches to Revolutionise Manufacturing and Supply
Speakers include:
Rebecca Vangenechten | Head Vertical Pharma Segment | Siemens
Chris Kopinski | Head of Strategy & Business Development HCLS/Manufacturing Industry Products | Amazon Web Services (AWS)
Paul Hardy | Client Executive Partner | Atos
Interviewed by:
Dave Tudor | Managing Director, Medicines Manufacturing Innovation Centre, Biologics & Quality | CPI